need break away shutdown
thesi updat perkin last qs confound us bit
headlin organ quit strong margin pull-through
uninspir given invest furthermor guid
consist disappoint manag ultim
beaten conserv guid made event
confer call least look forward pki transform
major player sever high growth market enjoy secular
tailwind point hsd growth potenti next sever
food/environment test cannabi genet test overal
reproduct health portfolio repres intrigu opportun
elev growth manag decis continu invest
area expand product portfolio view
posit light long-term howev struggl gain
confid recent acquisit euroimmun vanadi
former fallen short expect past qs although
report organ seem fine latter still infanc
without ton data custom check comparison
addit commentari around sever product pushout
variou govern action shutdown ministri health deal
restructur make us question near-term growth compani
abil maintain/acceler hsd growth may appar
lastli strain reach manag target
bp omx given near-term growth dynam given
pki elev multipl among highest tool keep us
sidelin gain clariti issu thu
reiter rate tweak pt
model/pt updat estim broadli move higher bump
core growth well construct gm expans
continu model conserv capit alloc thu
clear upsid potenti forecast would despit
rais omx assumpt still manag
forecast valuat rich will go
given upcom tough comp premium
all-tim high share core growth
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
biggest impact omx mix better
us government shutdown transient hw ep hw
dx core driven reproduct health ldd hsd
tulip genom test small base
transient impact government shutdown due product requir
natl secur push-out
place vanadi box plan place end yr
commentari contribut growth given
unclear strategi reagent rental vs outright sale
euroimmun margin lot runway take
bn capac look
euroimmun rev mm miss expect mm due
order ministri health push order sever
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin januari
analyst luke sergott ross muken primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
